tirzepatide and perimenopause GLP-1 Agonists in Perimenopause: Unique Risks Potential Opportunities Tirzepatide for Perimenopause Weight Gain

Healthcare professionals must conduct a thorough assessment before prescribing these treatments

Differences in Indications Wegovy was approved for cardiovascular risk reduction in March 2024

For patients with autoimmune thyroid disease, particularly Hashimoto's thyroiditis, there is no evidence that semaglutide adversely affects thyroid function or autoantibody levels

Rapid Weight Loss and Telogen Effluvium The most frequent explanation is rapid weight loss

The overall mean values for G6PD activity have to be optimized in individual laboratories to determine the cut-off points for moderate and severe G6PD deficiency